Guardant scores FDA approval for liquid biopsy test
In a phone interview, Guardant Health CEO Helmy Eltoukhy said he expected the approval to encourage coverage by those payers still on the sidelines.
Study finds Guardant’s liquid biopsy adept at detecting biomarker used by Merck immunotherapy drug
The study, by US and Korean researchers, found Guardant360's detection of MSI-H/dMMR "highly concordant" with that of standard tissue biopsy, including in a subset of gastric cancer patients who responded to immunotherapy.
presented by
5 Major Trends Emerging in Healthcare Benefits in 2025
Employees who enjoy their benefits are more inclined to stay with their company. A 2025 Marsh McLennan Agency report said 73% of employees would remain if plan options were better.
Liquid biopsy firm Guardant Health files for $100M IPO
The company, which has already raised more than $500 million in venture capital funding, would trade on the NASDAQ under the ticker symbol "GH."